TTrialPathMatch Me to Trials
← Back to trials
RecruitingBronchopulmonary DysplasiaPulmonary Hypertension

Pulmonary Hypertension and Oxygen Saturation Targeting in Preterm Infants

Eligible age

0.1–0.4 yrs

Accepts

All genders

Locations

2 states

Healthy volunteers

Yes

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

Around 50% of infants born extremely preterm develop a chronic lung disease known as bronchopulmonary dysplasia of which some infants will also develop pulmonary hypertension of which 50% of children will die before the age of 2. Physicians are currently limited in their ability to select the most appropriate oxygen targets that will improve outcomes in infants with this condition. This clinical trial will determine whether using different amounts of oxygen improve outcomes in infants with this disease.

Sponsor: University of Alabama at Birmingham

You may qualify if…

  • Between 22w 0/7d and 31w 6/7d gestation at birth
  • Diagnosed with echocardiographic pulmonary hypertension (1) \>20% flow of blood across the PDA from the pulmonary to arterial circulation, (2) end-systolic flattening of the interventricular septum (eccentricity index \>1.3), or (3) right ventricular pressure estimates ≥ 35 mm Hg
  • Receiving supplemental oxygen
  • Have mature retinas

You may not qualify if…

  • Major congenital anomalies

Where it's recruiting

Alabama

Birmingham

Connecticut

New Haven

Source: ClinicalTrials.gov · NCT06373289 · last updated 2026-08-26

Pulmonary Hypertension and Oxygen Saturation Targeting in Preterm Infa · TrialPath